A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT ID: NCT05552976
Last Updated: 2025-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
525 participants
INTERVENTIONAL
2023-01-10
2029-07-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)
Mezigdomide
Specified dose on specified days
Carfilzomib
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Kd (Carfilzomib + Dexamethasone)
Carfilzomib
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mezigdomide
Specified dose on specified days
Carfilzomib
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
i) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or.
ii) M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,.
iii) For participants without measurable disease in sPEP or uPEP: serum free light chain levels \> 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light chain ratio.
* Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, \[with or without\] hematopoietic stem cell transplant, (with or without) consolidation, and/or \[with or without\] maintenance therapy).
* Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received \< 2 cycles are still eligible).
* Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy.
* Participant must have documented disease progression during or after their last antimyeloma regimen.
Exclusion Criteria
* Participant has previously received allogeneic stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0046
Mobile, Alabama, United States
Local Institution - 0005
Cerritos, California, United States
Local Institution - 0190
Irvine, California, United States
Local Institution - 0187
Los Angeles, California, United States
Local Institution - 0344
Santa Rosa, California, United States
Local Institution - 0339
Stockton, California, United States
Local Institution - 0279
Newark, Delaware, United States
Local Institution - 0341
Fort Myers, Florida, United States
Local Institution - 0342
St. Petersburg, Florida, United States
Local Institution - 0340
West Palm Beach, Florida, United States
Local Institution - 0348
Atlanta, Georgia, United States
Local Institution - 0291
Atlanta, Georgia, United States
Saint Alphonsus Regional Medical Center
Boise, Idaho, United States
Local Institution - 0289
Annapolis, Maryland, United States
Local Institution - 0204
Boston, Massachusetts, United States
Local Institution - 0346
Minneapolis, Minnesota, United States
Local Institution - 0222
Little Silver, New Jersey, United States
Local Institution - 0199
The Bronx, New York, United States
University of North Carolina Medical Center
Chapel Hill, North Carolina, United States
Local Institution - 0322
Cleveland, Ohio, United States
Local Institution - 0172
Columbus, Ohio, United States
Local Institution - 0321
Providence, Rhode Island, United States
Charleston Oncology, P.A.
Charleston, South Carolina, United States
Local Institution - 0338
Greer, South Carolina, United States
Local Institution - 0349
Chattanooga, Tennessee, United States
Local Institution - 0323
Nashville, Tennessee, United States
Local Institution - 0337
Fort Worth, Texas, United States
Local Institution - 0328
Houston, Texas, United States
Local Institution - 0044
Houston, Texas, United States
Local Institution - 0195
Temple, Texas, United States
Local Institution - 0345
Norfolk, Virginia, United States
Local Institution - 0343
Roanoke, Virginia, United States
Local Institution - 0006
Tacoma, Washington, United States
Local Institution - 0347
Vancouver, Washington, United States
Local Institution - 0243
Morgantown, West Virginia, United States
Local Institution - 0336
Marshfield, Wisconsin, United States
Local Institution - 0008
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0079
ABB, Buenos Aires F.D., Argentina
Local Institution - 0182
Rosario, Santa Fe Province, Argentina
Local Institution - 0319
San Miguel de Tucumán, Tucumán Province, Argentina
Local Institution - 0150
Buenos Aires, , Argentina
Local Institution - 0151
Córdoba, , Argentina
Local Institution - 0077
Camperdown, New South Wales, Australia
Local Institution - 0160
Gosford, New South Wales, Australia
Local Institution - 0263
Port Macquarie, New South Wales, Australia
Local Institution - 0078
St Leonards, New South Wales, Australia
Local Institution - 0026
Sydney, New South Wales, Australia
Local Institution - 0024
Adelaide, South Australia, Australia
Local Institution - 0229
Hobart, Tasmania, Australia
Local Institution - 0131
Bendigo, Victoria, Australia
Local Institution - 0224
East Melbourne, Victoria, Australia
Local Institution - 0127
Heidelberg, Victoria, Australia
Local Institution - 0025
Melbourne, Victoria, Australia
Local Institution - 0266
Vienna, Vienna, Austria
Local Institution - 0020
Linz, , Austria
Local Institution - 0017
Vienna, , Austria
Local Institution - 0119
Vienna, , Austria
Local Institution - 0121
Salvador, Estado de Bahia, Brazil
Local Institution - 0076
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 0085
São Paulo, São Paulo, Brazil
Local Institution - 0075
Rio de Janeiro, , Brazil
Local Institution - 0086
Rio de Janeiro, , Brazil
Local Institution - 0073
São Paulo, , Brazil
University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD
Plovdiv, , Bulgaria
Acibadem City Clinic University Multiprofile Hospital for Active Treatment Tokuda EAD
Sofia, , Bulgaria
UMHAT 'Sveti Ivan Rilsky'
Sofia, , Bulgaria
Local Institution - 0183
Halifax, Nova Scotia, Canada
Local Institution - 0275
London, Ontario, Canada
Local Institution - 0184
Toronto, Ontario, Canada
Local Institution - 0186
Montreal, Quebec, Canada
Local Institution - 0318
Hefei, Anhui, China
Local Institution - 0061
Beijing, Beijing Municipality, China
Local Institution - 0057
Beijing, Beijing Municipality, China
Local Institution - 0056
Beijing, Beijing Municipality, China
Local Institution - 0123
Fuzhou, Fujian, China
Local Institution - 0138
Guangzhou, Guangdong, China
Local Institution - 0315
Guangzhou, Guangdong, China
Local Institution - 0051
Zhengzhou, Henan, China
Local Institution - 0066
Wuhan, Hubei, China
Local Institution - 0054
Wuhan, Hubei, China
Local Institution - 0071
Changsha, Hunan, China
Local Institution - 0103
Changsha, Hunan, China
Local Institution - 0180
Nanjing, Jiangsu, China
Local Institution - 0111
Nantong, Jiangsu, China
Local Institution - 0104
Suzhou, Jiangsu, China
Local Institution - 0069
Wuxi, Jiangsu, China
Local Institution - 0095
Nanchang, Jiangxi, China
Local Institution - 0052
Changchun, Jilin, China
Local Institution - 0096
Shenyang, Liaoning, China
Local Institution - 0176
Shenyang, Liaoning, China
Local Institution - 0060
Xi'an, Shaanxi, China
Local Institution - 0072
Jinan, Shandong, China
Local Institution - 0118
Shanghai, Shanghai Municipality, China
Local Institution - 0317
Shanghai, Shanghai Municipality, China
Local Institution - 0091
Tianjin, Tianjin Municipality, China
Local Institution - 0058
Kunming, Yunnan, China
Local Institution - 0050
Hangzhou, Zhejiang, China
Local Institution - 0115
Wenzhou, Zhejiang, China
Local Institution - 0059
Taiyuan, , China
Local Institution - 0153
Medellín, Antioquia, Colombia
Local Institution - 0156
Valledupar, Cesar Department, Colombia
Local Institution - 0154
Bogota, Cundinamarca, Colombia
Local Institution - 0324
Piedecuesta, Santander Department, Colombia
Local Institution - 0155
Cali, , Colombia
Local Institution - 0032
Aarhus, Central Jutland, Denmark
Local Institution - 0065
Roskilde, Region Sjælland, Denmark
Local Institution - 0129
Odense, Region Syddanmark, Denmark
Local Institution - 0125
Vejle, , Denmark
Universitaetsklinikum Ulm
Ulm, Baden-Wurttemberg, Germany
Haematologie und Onkologie Muenchen-Pasing
Munich, Bavaria, Germany
Klinikum Nuernberg Nord, Urologische Klinik
Nuremberg, Bavaria, Germany
Praxis Onkologie am Raschplatz
Hanover, Lower Saxony, Germany
GEFOS Gesellschaft f. onkologische Studien
Dortmund, North Rhine-Westphalia, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel
Kiel, Schleswig-Holstein, Germany
Universitätsklinikum Jena
Jena, Thuringia, Germany
Charite Universitätsmedizin Berlin Campus Benjamin Franklin
Berlin, , Germany
Local Institution - 0102
Cologne, , Germany
Universitaetsklinikum Carl Gustav Carus Dresden
Dresden, , Germany
Marien Hospital Düsseldorf
Düsseldorf, , Germany
Universitaetsklinikum Heidelberg
Heidelberg, , Germany
Universitätsklinikum Leipzig
Leipzig, , Germany
Universitaetsklinikum Wuerzburg
Würzburg, , Germany
Local Institution - 0136
Pátrai, Achaḯa, Greece
Local Institution - 0135
Athens, Attikí, Greece
Local Institution - 0134
Thessaloniki, Thessaloníki, Greece
Local Institution - 0178
Hksar, , Hong Kong
Pécsi Tudományegyetem Klinikai Központ
Pécs, Baranya, Hungary
Debreceni Egyetem Klinikai Kozpont
Debrecen, Hajdú-Bihar, Hungary
Szabolcs Szatmár Bereg Vármegyei Oktatókórház
Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary
Semmelweis Egyetem
Budapest, , Hungary
Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
Budapest, , Hungary
Local Institution - 0167
Gurgaon, Haryana, India
Local Institution - 0161
Bengaluru, Karnataka, India
Local Institution - 0168
Mumbai, Maharashtra, India
Local Institution - 0171
Thāne, Maharashtra, India
Local Institution - 0170
New Delhi, National Capital Territory of Delhi, India
Local Institution - 0261
Mohali, Punjab, India
Local Institution - 0174
Chennai, Tamil Nadu, India
Local Institution - 0165
Hyderabad, Telangana, India
Local Institution - 0310
Hyderabad, Telangana, India
Local Institution - 0164
Hyderabad, Telangana, India
Local Institution - 0230
Chandigarh, , India
Local Institution - 0264
Holon, Central District, Israel
Local Institution - 0267
Ẕerifin, Central District, Israel
Local Institution - 0277
Jerusalem, , Israel
Local Institution - 0145
Meldola, Emilia-Romagna, Italy
Local Institution - 0143
Milan, Lombardy, Italy
Local Institution - 0142
Rozzano, Milano, Italy
Local Institution - 0189
Bologna, , Italy
Local Institution - 0148
Catanzaro, , Italy
Local Institution - 0147
Lecce, , Italy
Local Institution - 0144
Pisa, , Italy
Local Institution - 0146
Udine, , Italy
Local Institution - 0269
Nagoya, Aichi-ken, Japan
Local Institution - 0214
Kashiwa, Chiba, Japan
Local Institution - 0210
Kitakyushu-shi, Fukuoka, Japan
Local Institution - 0211
Sapporo, Hokkaido, Japan
Local Institution - 0217
Higashiibaraki, Ibaraki, Japan
Local Institution - 0300
Kanazawa, Ishikawa-ken, Japan
Local Institution - 0209
Shiwa-gun Yahaba-cho, Iwate, Japan
Local Institution - 0234
Kamakura, Kanagawa, Japan
Local Institution - 0225
Koshigaya, Saitama, Japan
Local Institution - 0236
Itabashiku, Tokyo, Japan
Local Institution - 0219
Koto-ku, Tokyo, Japan
Local Institution - 0303
Chūō, Yamanashi, Japan
Local Institution - 0215
Chiba, , Japan
Local Institution - 0226
Fukuoka, , Japan
Local Institution - 0235
Fukuoka, , Japan
Local Institution - 0220
Kumamoto, , Japan
University Hospital,Kyoto Prefectural University of Medicine
Kyoto, , Japan
Local Institution - 0213
Nagasaki, , Japan
Local Institution - 0212
Okayama, , Japan
Local Institution - 0301
Osaka, , Japan
Local Institution - 0241
Tokyo, , Japan
Local Institution - 0218
Tokyo, , Japan
Amphia Ziekenhuis, locatie Breda Molengracht
Breda, North Brabant, Netherlands
Medisch Spectrum Twente
Enschede, , Netherlands
Local Institution - 0049
Bergen, Hordaland, Norway
Local Institution - 0112
Stavanger, Rogaland, Norway
Local Institution - 0081
Oslo, , Norway
Local Institution - 0316
San Juan, , Puerto Rico
Fundeni Clinical Institute
Bucharest, București, Romania
Local Institution - 0290
Timișoara, Timiș County, Romania
Sc Onco Card Srl
Brasov, , Romania
Affidea Fundeni
Bucharest, , Romania
Spitalul Clinic Colțea
Bucharest, , Romania
Spitalul Clinic Județean de Urgență Sibiu
Sibiu, , Romania
Local Institution - 0158
Singapore, Central Singapore, Singapore
Local Institution - 0159
Singapore, Central Singapore, Singapore
Local Institution - 0238
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Local Institution - 0239
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Local Institution - 0240
Seoul, Seoul-teukbyeolsi [Seoul], South Korea
Local Institution - 0126
Badalona, Barcelona [Barcelona], Spain
Local Institution - 0092
Barcelona, Barcelona [Barcelona], Spain
Local Institution - 0038
L'Hospitalet Del Llobregat, Barcelona [Barcelona], Spain
Local Institution - 0200
Madrid, Madrid, Comunidad de, Spain
Local Institution - 0108
Majadahonda, Madrid, Comunidad de, Spain
Local Institution - 0192
San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain
Local Institution - 0201
San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain
Local Institution - 0037
Valencia, Valenciana, Comunitat, Spain
Local Institution - 0107
Granada, , Spain
Local Institution - 0047
Madrid, , Spain
Local Institution - 0105
Málaga, , Spain
Local Institution - 0274
Chiayi City, Chiayi, Taiwan
Local Institution - 0177
Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan
Local Institution - 0012
Kaohsiung City, , Taiwan
Local Institution - 0001
Taichung, , Taiwan
Local Institution - 0002
Tainan, , Taiwan
Local Institution - 0149
Taipei, , Taiwan
Local Institution - 0162
Taipei, , Taiwan
Local Institution - 0139
Plymouth, Devon, United Kingdom
Local Institution - 0067
Cringleford, England, United Kingdom
Local Institution - 0196
Glasgow, Glasgow City, United Kingdom
Local Institution - 0039
Birmingham, , United Kingdom
Local Institution - 0273
Birmingham, , United Kingdom
Local Institution - 0080
Leeds, , United Kingdom
Local Institution - 0040
Taunton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role: CONTACT
Phone: 855-907-3286
Email: [email protected]
First line of the email MUST contain the NCT# and Site #.
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site 0279
Role: primary
Bobby Chawla, Site 0203
Role: primary
Vasko Graklanov, Site 0305
Role: primary
Ismail Amine, Site 0309
Role: primary
Atanas Radinoff, Site 0304
Role: primary
Site 0318
Role: primary
Site 0315
Role: primary
Miriam Kull, Site 0124
Role: primary
Burkhard Schmidt, Site 0330
Role: primary
Stefan Knop, Site 0133
Role: primary
Eyck von der Heyde, Site 0333
Role: primary
Joerg Lipke, Site 0335
Role: primary
Natalie Schub, Site 0029
Role: primary
Olaposi Yomade, Site 0331
Role: primary
Stephan Bohl, Site 0007
Role: primary
Karolin Trautmann-Grill, Site 0329
Role: primary
Maika Klaiber-Hakimi, Site 0334
Role: primary
Marc-Steffen Raab, Site 0015
Role: primary
Simone Heyn, Site 0030
Role: primary
Martin Kortuem, Site 0014
Role: primary
Szabolcs Kosztolányi, Site 0036
Role: primary
Arpad Illes, Site 0043
Role: primary
Laszlo Rejto, Site 0094
Role: primary
Gergely Varga, Site 0042
Role: primary
Gabor MIKALA Dr, Site 0019
Role: primary
Junya Kuroda, Site 0216
Role: primary
Marjolein van der Klift, Site 0113
Role: primary
Cleo Rooijen, van, Site 0194
Role: primary
Sorina Badelita, Site 0282
Role: primary
Mihaela Lazaroiu, Site 0284
Role: primary
Mihaela Andreescu, Site 0302
Role: primary
ANDREI COLITA, Site 0287
Role: primary
ALINA CATANA, Site 0306
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA057-008
Identifier Type: -
Identifier Source: org_study_id